Affinity DataKi: 1.00E+3nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 6.00E+3nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:Inhibition of human recombinant GST-tagged JAK1 catalytic domain (866 to 1154 residues) expressed in baculovirus expression system by Z'-lyte assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.10nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.30nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Rigel Pharmaceuticals
US Patent
Rigel Pharmaceuticals
US Patent
Affinity DataIC50: 7.90nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo™ technology. ADP-Glo™ (Promega, Madison, Wis....More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2/Tyrosine-protein kinase JAK1(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of JAK1/TYK2 signaling pathway in human primary T-cells assessed as reduction of IFN-alpha induced STAT1 phosphorylationMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of TAK1 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Rigel Pharmaceuticals
US Patent
Rigel Pharmaceuticals
US Patent
Affinity DataIC50: 8.10nMAssay Description:ADP-Glo (Promega, Madison, Wis., USA) reagents were thawed at ambient temperature. Kinase Detection Reagent was prepared by mixing kinase detection b...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Rigel Pharmaceuticals
US Patent
Rigel Pharmaceuticals
US Patent
Affinity DataIC50: 8.30nMAssay Description:ADP-Glo (Promega, Madison, Wis., USA) reagents were thawed at ambient temperature. Kinase Detection Reagent was prepared by mixing kinase detection b...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Rigel Pharmaceuticals
US Patent
Rigel Pharmaceuticals
US Patent
Affinity DataIC50: 8.5nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo™ technology. ADP-Glo™ (Promega, Madison, Wis....More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of JAK1/JAK3 in human primary T-cells assessed as reduction of IL-2 stimulated STAT5 phosphorylation preincubated for 1 hr followed by IL-...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Rigel Pharmaceuticals
US Patent
Rigel Pharmaceuticals
US Patent
Affinity DataIC50: 9.80nMAssay Description:ADP-Glo (Promega, Madison, Wis., USA) reagents were thawed at ambient temperature. Kinase Detection Reagent was prepared by mixing kinase detection b...More data for this Ligand-Target Pair
TargetReceptor-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Rigel Pharmaceuticals
US Patent
Rigel Pharmaceuticals
US Patent
Affinity DataIC50: 9.90nMAssay Description:In this example, compounds of the disclosure were evaluated using a biochemical assay using the ADP-Glo™ technology. ADP-Glo™ (Promega, Madison, Wis....More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Rigel Pharmaceuticals
Curated by ChEMBL
Rigel Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of MBP as substrate by ADP-Glo assayMore data for this Ligand-Target Pair